Google
RGEN Stock Analysis — REPLIGEN CORPORATION (Healthcare >> Medical Instruments & Supplies)
RGEN FAQ
What is RGEN's P/E ratio?
REPLIGEN CORPORATION (RGEN) currently trades at a P/E ratio of 195.10.
What is RGEN's ROE?
REPLIGEN CORPORATION reports a Return on Equity (ROE) of 1.97%.
What is RGEN's dividend yield?
REPLIGEN CORPORATION offers a dividend yield of 0.00%.
What is RGEN's Quality Score?
Our AI rates RGEN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RGEN?
Our AI Timing Score for RGEN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RGEN belong to?
REPLIGEN CORPORATION is classified under the Healthcare >> Medical Instruments & Supplies sector on the NASDAQ exchange
RGEN AI Analysis Summary
Our AI summary for RGEN: REPLIGEN CORPORATION (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 195.10, ROE of 1.97%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 141.01
Price
-2.59
(-1.80%)
Day Change
|
|
|---|
RGEN, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
2947
|
| Magic Formula Rank by ROE |
2947
|
| Magic Formula Rank by ROIC |
2962
|
| Price | 141.01 |
| PBV / Sector |
3.84 / 3.37
|
| Earning Per Share | 0.72 |
| PE / Sector |
195.10 / 44.25
|
| PEG or PE/Growth / Sector |
-1.11 / -1.35
|
| Average 1M Daily Value |
167.99 M
GREAT
|
| Average 1W Daily Value |
203.82 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:24 |
| Symbol | RGEN |
| Name | REPLIGEN CORPORATION |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 56.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,104.16 / 16,159.14 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 1, Waltham, MA, United States, 02453
Phone: 781 250 0111
Website: https://www.repligen.com
Employees: 2,000
Description: Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Medical Instruments & SuppliesAnalysed on the same criteria, ordered by market cap